Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-AE105 PET imaging in breast, prostate, and bladder cancer
NCT02437539Phase 1Completed
- Sponsor
- Rigshospitalet
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of 68Ga-NOTA-AE105 in breast cancer, prostate cancer (PCa) and bladder cancer, sponsored by Rigshospitalet. Primary endpoints: Biodistribution at 2 hours, Dosimetry at 2 hours and 1 more. Started May 2015; status: completed.
02
Drugs
68Ga-NOTA-AE105
03
Conditions
breast cancerprostate cancer (PCa)bladder cancer
Beyond the preview
Go deeper on NCT02437539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437539.